Recombinant Human Erythropoietin/EPO (Ultrapure) Protein, CF
Recombinant Human Erythropoietin/EPO (Ultrapure) Protein, CF Summary
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Supplied as a 0.2 μm filtered solution in PBS.|
|Shipping||The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated
• 12 months from date of receipt at -20 to -70 °C as supplied.
• 1 month at 2-8 °C under sterile conditions after reconstitution.
• 3 months at -20 to -70 °C under sterile conditions after reconstitution.
Erythropoietin (EPO) is a 34 kDa glycoprotein hormone in the type I cytokine family and is related to thrombopoietin (1). Its three N-glycosylation sites, four alpha helices, and N- to C-terminal disulfide bond are conserved across species (2, 3). Glycosylation of EPO is required for biological activities in vivo (4). Mature human EPO shares 75%-84% amino acid sequence identity with bovine, canine, equine, feline, mouse, ovine, porcine, and rat EPO. EPO is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules (5). It is also produced in much lower, but functionally significant amounts by fetal hepatocytes and in adult liver and brain (6-8). EPO promotes erythrocyte formation by preventing the apoptosis of early erythroid precursors which express the EPO receptor (EPO R) (8, 9). EPO R has also been described in brain, retina, heart, skeletal muscle, kidney, endothelial cells, and a variety of tumor cells (7, 8, 10, 11). Ligand induced dimerization of EPO R triggers JAK2-mediated signaling pathways followed by receptor/ligand endocytosis and degradation (1, 12). Rapid regulation of circulating EPO allows tight control of erythrocyte production and hemoglobin concentrations. Anemia or other causes of low tissue oxygen tension induce EPO production by stabilizing the hypoxia-induceable transcription factors HIF-1 alpha and HIF-2 alpha (1, 6). EPO additionally plays a tissue-protective role in ischemia by blocking apoptosis and inducing angiogenesis (7, 8, 13).
- Koury, M. J. (2005) Exp. Hematol. 33:1263.
- Jacobs, K. et al. (1985) Nature 313:806.
- Wen, D. et al. (1993) Blood 82:1507.
- Tsuda E., et al. (1990) Eur. J. Biochem. 188:405.
- Lacombe, C. et al. (1988) J. Clin. Invest. 81:620.
- Eckardt, K. U. and A. Kurtz (2005) Eur. J. Clin. Invest. 35: Suppl. 3:13.
- Sharples, E. J. et al. (2006) Curr. Opin. Pharmacol. 6:184.
- Rossert, J. and K. Eckardt (2005) Nephrol. Dial. Transplant 20:1025.
- Koury, M.J. and M.C. Bondurant (1990) Science 248:378.
- Acs, G. et al. (2001) Cancer Res. 61:3561.
- Hardee, M.E. et al. (2006) Clin. Cancer Res. 12:332.
- Verdier, F. et al. (2000) J. Biol. Chem. 275:18375.
- Kertesz, N. et al. (2004) Dev. Biol. 276:101.
Citations for Recombinant Human Erythropoietin/EPO (Ultrapure) Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 6
Filter your results:
Discrimination of Dormant and Active Hematopoietic Stem Cells by G0 Marker Reveals Dormancy Regulation by Cytoplasmic Calcium
Authors: T Fukushima, Y Tanaka, FK Hamey, CH Chang, T Oki, S Asada, Y Hayashi, T Fujino, T Yonezawa, R Takeda, KC Kawabata, T Fukuyama, T Umemoto, K Takubo, H Takizawa, S Goyama, Y Ishihama, H Honda, B Göttgens, T Kitamura
Cell Rep, 2019-12-17;29(12):4144-4158.e7.
Sample Types: Whole Cells
Applications: Cell Culture
Erythropoietin Treatment Exacerbates Moderate Injury after Hypoxia-Ischemia in Neonatal Superoxide Dismutase Transgenic Mice
Authors: RA Sheldon, C Windsor, BS Lee, O Arteaga Ca, DM Ferriero
Dev. Neurosci., 2017-04-27;0(0):.
Sample Types: In Vivo
Applications: In Vivo
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system
Gene Ther., 2016-06-30;23(10):699-707.
Sample Types: Protein
Applications: ELISA (Control)
Dynamic interaction networks in a hierarchically organized tissue.
Authors: Kirouac DC, Ito C, Csaszar E, Roch A, Yu M, Sykes EA, Bader GD, Zandstra PW
Mol. Syst. Biol., 2010-10-05;6(0):417.
Sample Types: Whole Cells
SLAM family markers are conserved among hematopoietic stem cells from old and reconstituted mice and markedly increase their purity.
Authors: Yilmaz OH, Kiel MJ, Morrison SJ
Sample Types: Whole Cells
Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver.
Authors: Barcena A, Park SW, Banapour B, Muench MO, Mechetner E
Reviews for Recombinant Human Erythropoietin/EPO (Ultrapure) Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human Erythropoietin/EPO (Ultrapure) Protein, CF and earn rewards!
Have you used Recombinant Human Erythropoietin/EPO (Ultrapure) Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image